Diagnostic accuracy of osteopontin for malignant pleural mesothelioma: A systematic review and meta-analysis

Hu, Zhide; Liu, Xiaofei; Liu, Xiaocui; Ding, Chun-Mei; Hu, Chengjin

doi:10.1016/j.cca.2014.02.024

Cited by 46 publications

(40 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A more recent systematic review and meta-analysis evaluated the overall diagnostic accuracy of serum OPN measurement for diagnosing MM (64). The results of this study showed that pooled sensitivity was 57% (95% CI 52-61%), and specificity was 81% (95% CI 79-84%), the area under the curve (AUC) of the receiver operating characteristic (ROC) curve being 0.80.…”

Section: Osteopontin (Opn)mentioning

confidence: 71%

“…The results of this study showed that pooled sensitivity was 57% (95% CI 52-61%), and specificity was 81% (95% CI 79-84%), the area under the curve (AUC) of the receiver operating characteristic (ROC) curve being 0.80. These data suggested that OPN was a helpful diagnostic biomarker for MM (64).…”

Section: Osteopontin (Opn)mentioning

confidence: 92%

“…Novel, and potentially more sensitive and specific MM biomarkers were evaluated, including MPF(31), OPN (60,64,66), fibulin-3 (70,72,73), HMGB1 (82), with promising results. In addition, a variety of deregulated miRNAs [reviewed in (109)], including the miR-score signature with prognostic significance (98), as well as different approaches based on proteomics technology, have been proposed as suitable MM markers (100,109).…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Diagnostic and prognostic biomarkers for malignant mesothelioma: an update

Chen

Gaudino

Pass

et al. 2017

Transl. Lung Cancer Res.

View full text Add to dashboard Cite

Malignant mesothelioma (MM) is an aggressive and lethal cancer, mostly related to inhalation of asbestos and erionite fibers. MM is associated with poor prognosis, because of its resistance to current therapies, even if higher survival occurs in patients diagnosed and treated when at stage I of the disease.However, these do not exceed 5% of the total number of cases, due to the inadequacy of the existing biomarkers for early and accurate diagnosis. Therefore, new effective biomarkers are needed for MM detection at earlier stages and to develop tailored therapies. Here we review the most promising biomarkers in MM to date: mesothelin, soluble mesothelin-related peptides (SMRPs), megakaryocyte potentiating factor (MPF), Osteopontin (OPN), Fibulin-3, high mobility group B1 (HMGB1), microRNAs (miRNAs), multiplex protein signatures. The validation of these biomarkers will allow their use, alone or in combination, for monitoring individuals from cohorts at risk of MM and attaining early detection of MM that is instrumental in improving patient survival.

show abstract

Section: Osteopontin (Opn)mentioning

confidence: 71%

Section: Osteopontin (Opn)mentioning

confidence: 92%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Diagnostic and prognostic biomarkers for malignant mesothelioma: an update

Chen

Gaudino

Pass

et al. 2017

Transl. Lung Cancer Res.

View full text Add to dashboard Cite

show abstract

“…Nevertheless, further studies with a larger sample size and better design are needed to carefully assess the diagnostic power of this biomarker (25).…”

Section: Osteopontin (Opn)mentioning

confidence: 99%

“…Other authors confirmed OPN as an effective marker for MPM diagnosis (22,(25)(26)(27)(28) and the utility as biological markers for the health surveillance of past-exposed patients (28). Nevertheless, further studies with a larger sample size and better design are needed to carefully assess the diagnostic power of this biomarker (25).…”

Section: Osteopontin (Opn)mentioning

confidence: 99%

Serum mesothelin and other biomarkers: what have we learned in the last decade?

et al. 2018

View full text Add to dashboard Cite

In the last decade there is been much interest in noninvasive, economic and well-accepted diagnostic tests for screening of subjects exposed to asbestos, and in patients with malignant pleuric mesothelioma (MPM) for diagnosis or monitoring response to treatment. Several biomarkers have been suggested as tools for screening and early diagnosis of MPM. Currently, in patients with MPM, have been reported high levels of soluble mesothelin-related peptides (SMRP), plasmatic osteopontin (pOPN), vimentin, fibulin-3 and many others as promising marker for diagnosis, even their use in prevention monitoring is still discussed. In this type of disease, a key role could be played by miRNAs, which expression has been investigated in a large series of MPM to examine new pathways useful in diagnosis, prognosis and therapy. An altered expression of some proteins has been reported, useful as biomarkers, in comparative proteomic analysis of malignant pleural mesothelioma. New promising markers are nowadays under study and alone or better in combination, they'll be very helpful in diagnosing, monitoring mesothelioma patients or for screening of risk groups.

show abstract